XTX Topco Ltd Invests $198,000 in Cryoport, Inc. (NASDAQ:CYRX)

XTX Topco Ltd acquired a new position in shares of Cryoport, Inc. (NASDAQ:CYRX) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 28,684 shares of the company’s stock, valued at approximately $198,000. XTX Topco Ltd owned approximately 0.06% of Cryoport as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Conestoga Capital Advisors LLC lifted its stake in shares of Cryoport by 1.0% during the first quarter. Conestoga Capital Advisors LLC now owns 71,417 shares of the company’s stock valued at $1,264,000 after acquiring an additional 690 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of Cryoport by 3.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 48,522 shares of the company’s stock valued at $859,000 after purchasing an additional 1,438 shares during the last quarter. Comerica Bank grew its position in shares of Cryoport by 73.0% during the 1st quarter. Comerica Bank now owns 3,481 shares of the company’s stock worth $62,000 after buying an additional 1,469 shares during the period. Natixis Investment Managers International raised its stake in shares of Cryoport by 61.5% during the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after buying an additional 1,727 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Cryoport by 3.4% in the second quarter. Rhumbline Advisers now owns 64,158 shares of the company’s stock valued at $443,000 after buying an additional 2,086 shares during the period. 92.90% of the stock is currently owned by institutional investors.

Cryoport Trading Up 0.4 %

NASDAQ:CYRX opened at $8.00 on Monday. The company has a debt-to-equity ratio of 0.97, a current ratio of 8.38 and a quick ratio of 7.99. The business’s 50-day simple moving average is $8.51 and its 200-day simple moving average is $11.27. Cryoport, Inc. has a fifty-two week low of $5.32 and a fifty-two week high of $20.10. The stock has a market capitalization of $394.06 million, a PE ratio of -3.24 and a beta of 1.60.

Cryoport (NASDAQ:CYRX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($1.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($1.25). Cryoport had a negative net margin of 76.48% and a negative return on equity of 15.55%. The company had revenue of $57.60 million during the quarter, compared to the consensus estimate of $57.65 million. During the same period in the previous year, the firm posted ($0.42) EPS. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. Sell-side analysts expect that Cryoport, Inc. will post -1.63 earnings per share for the current fiscal year.

Cryoport announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, August 6th that allows the company to repurchase $200.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 49.1% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s management believes its shares are undervalued.

Insiders Place Their Bets

In other Cryoport news, Director Ramkumar Mandalam sold 4,167 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $8.04, for a total transaction of $33,502.68. Following the completion of the transaction, the director now owns 56,032 shares of the company’s stock, valued at approximately $450,497.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 7,167 shares of company stock worth $60,363. Corporate insiders own 10.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on CYRX. Jefferies Financial Group lowered shares of Cryoport from a “buy” rating to a “hold” rating and lowered their target price for the stock from $20.00 to $8.00 in a report on Wednesday, August 7th. Needham & Company LLC reduced their target price on Cryoport from $18.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday, August 7th. B. Riley raised Cryoport from a “neutral” rating to a “buy” rating and lowered their price target for the company from $19.00 to $15.00 in a research note on Wednesday, July 31st. Finally, UBS Group reduced their price objective on shares of Cryoport from $17.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, Cryoport currently has an average rating of “Hold” and a consensus target price of $11.60.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.